Form 4: Vertex Pharmaceuticals EVP, Chief Scientific Officer David Altshuler Reports Stock Sale

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reports the sale of 3,231 shares of common stock at $500 per share on March 10, 2025, according to a Form 4 filing.

Summary

• David Altshuler, the EVP and Chief Scientific Officer of Vertex Pharmaceuticals, filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 10, 2025.
• Altshuler sold 3,231 shares of Vertex Pharmaceuticals common stock at a price of $500 per share.
• The sale was executed under a pre-arranged trading plan (Rule 10b5-1) established on August 8, 2024.
• Following the transaction, Altshuler directly owns 26,512 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine insider transaction under a pre-arranged trading plan. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

Insider sales are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects. However, large or frequent sales can sometimes be viewed negatively by investors.

Stakeholder Impact

• The sale of shares by a high-ranking executive could potentially cause short-term uncertainty among shareholders, although the pre-arranged trading plan mitigates this concern.

Key Dates